European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application
benzinga_article·- The European Medicines Agency validated the Marketing Authorization Application for Pfizer and Valneva's Lyme disease vaccine candidate, PF-07307405. - The application is supported by Phase 3 VALOR clinical trial data evaluating the vaccine in individuals aged 5 and older. - Valneva shares surged 24.96% to $7.06 following the announcement.Valneva (NASDAQ:VALN) Issues Earnings Results, Misses Expectations By $0.17 EPS
Market Beat·- Valneva reported a quarterly earnings per share loss of $ 0.40 and revenue of $ 39.37 million, both missing analyst expectations. - The company experienced a negative net margin of 88.87 % and a negative return on equity of 107.63 %. - Meanwhile, the European Medicines Agency validated the marketing authorization application for its co-developed Lyme disease vaccine candidate.Nuo Therapeutics Q2 FY26 revenue more than doubles to $1.77 million; gross profit climbs to $1.17 million
PUBT·- Nuo Therapeutics reported its Q2 FY 26 revenue more than doubled year over year to USD 1.77 million, driven by Aurix growth, with a gross profit of USD 1.17 million. - Operating expenses increased to USD 1.34 million due to higher compensation and third-party commissions, while six-month revenue rose 163 % to USD 3.07 million. - Supply risk heightened after a Pfizer warning regarding TJMI thrombin unavailability until early 2027 caused a temporary Aurix out-of-stock in August 2026.